<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347123</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 24360-208 (ECHO-208)</org_study_id>
    <nct_id>NCT03347123</nct_id>
  </id_info>
  <brief_title>A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)</brief_title>
  <official_title>A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, and efficacy of
      epacadostat when given in combination with nivolumab and ipilimumab, and in combination with
      nivolumab and lirilumab, in subjects with advanced or metastatic malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]</measure>
    <time_frame>Up to approximately 18 months per subject.</time_frame>
    <description>TEAEs defined as any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Objective response rate (ORR) based on Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1)</measure>
    <time_frame>At protocol-specified timepoints up to approximately 18 months per subject.</time_frame>
    <description>Defined as the percentage of subjects having complete response (CR) or partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: ORR based on RECIST v1.1</measure>
    <time_frame>Every 8 weeks for 12 months and then every 12 weeks, up to approximately 18 months per subject.</time_frame>
    <description>Defined as the percentage of subjects having CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; Phase 2: Duration of response</measure>
    <time_frame>Every 8 weeks for 12 months and then every 12 weeks, up to approximately 18 months per subject.</time_frame>
    <description>Defined as the time from the earliest date of CR or PR until the earliest date at which progression criteria are met or date of death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; Phase 2: Progression-free survival</measure>
    <time_frame>Every 8 weeks for 12 months and then every 12 weeks, up to approximately 18 months per subject.</time_frame>
    <description>Defined as the time from the start of combination therapy until the earliest date at which progression criteria are met per RECIST v1.1 or date of death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]</measure>
    <time_frame>Screening through up to 150 days after end of treatment, up to approximately 18 months per subject.</time_frame>
    <description>TEAEs defined as any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epacadostat + nivolumab + ipilimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epacadostat + nivolumab + lirilumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epacadostat</intervention_name>
    <description>Phase 1: Epacadostat at the protocol-defined dose twice daily. Phase 2: Epacadostat at the recommended dose from Phase 1.</description>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_label>Treatment Group B</arm_group_label>
    <other_name>INCB024360</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab at the protocol-specified dose and schedule.</description>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_label>Treatment Group B</arm_group_label>
    <other_name>Opdivo®</other_name>
    <other_name>BMS-936558</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab at the protocol-specified dose and schedule.</description>
    <arm_group_label>Treatment Group A</arm_group_label>
    <other_name>Yervoy®</other_name>
    <other_name>BMS-734016</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lirilumab</intervention_name>
    <description>Lirilumab at the protocol-specified dose and schedule.</description>
    <arm_group_label>Treatment Group B</arm_group_label>
    <other_name>IPH2102</other_name>
    <other_name>BMS-986015</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  During Phase 1, subjects with locally advanced or metastatic solid tumors with disease
             progression on or after treatment with available therapies, or who are intolerant to
             treatment, or who refuse standard treatment.

          -  During Phase 2, subjects with advanced cancer who have received at least one prior
             therapy or are treatment naive, depending on the specified tumor type.

          -  Presence of measurable disease per RECIST v1.1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Expected survival of ≥ 12 weeks.

        Exclusion Criteria:

          -  Laboratory and medical history parameters not within the Protocol-defined range.

          -  Receipt of anticancer medications or investigational drugs within Protocol-defined
             time frames.

          -  Previous radiotherapy within 7 days of Cycle 1 Day 1.

          -  Known active central nervous system metastases and/or carcinomatous meningitis.

          -  Prior treatment with any immune checkpoint inhibitor and/or an IDO inhibitor.

          -  Active infection requiring systemic therapy.

          -  Any active or inactive autoimmune disease or syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pia Baumann, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epacadostat</keyword>
  <keyword>nivolumab</keyword>
  <keyword>ipilimumab</keyword>
  <keyword>lirilumab</keyword>
  <keyword>solid tumor</keyword>
  <keyword>melanoma</keyword>
  <keyword>non-small cell lung cancer (NSCLC)</keyword>
  <keyword>squamous cell carcinoma of the head and neck (SCCHN)</keyword>
  <keyword>IDO inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

